封面
市场调查报告书
商品编码
1738323

癌症诊断人工智慧市场—全球产业规模、份额、趋势、机会和预测(按技术、癌症类型、最终用户、地区和竞争细分,2020-2030 年)

Artificial Intelligence In Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Cancer Type, By End-User, By Region & Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024年,全球癌症诊断人工智慧市场规模达1.2847亿美元,预计将大幅成长,到2030年将达到2.0862亿美元,预测期内复合年增长率为8.54%。人工智慧正在改变癌症诊断方式,透过分析影像扫描和基因组图谱等复杂医学资料,能够更快、更准确地检测出恶性肿瘤。随着全球癌症发生率的上升,对能够改善临床疗效的早期检测工具的需求也不断增长。人工智慧诊断平台可以识别传统方法无法识别的资料中的细微模式,提高诊断准确性,同时减少诊断时间和人为错误。这对于乳癌、肺癌和大肠癌等高负担癌症尤其重要。技术进步、癌症盛行率的上升以及对精准医疗的大力推动是推动市场扩张的关键因素。此外,DELFI的肝癌人工智慧血液检测等成功应用凸显了人工智慧在改善早期诊断和长期存活率方面的潜力。

市场概览
预测期 2026-2030
2024年市场规模 1.2847亿美元
2030年市场规模 2.084亿美元
2025-2030 年复合年增长率 8.54%
成长最快的领域 医院
最大的市场 北美洲

关键市场驱动因素

癌症发生率上升和早期检测需求推动全球癌症诊断人工智慧市场的发展

主要市场挑战

数据品质和数量对市场扩张构成重大障碍

主要市场趋势

技术进步

目录

第 1 章:产品概述

第二章:研究方法

第三章:执行摘要

第四章:全球癌症诊断人工智慧市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 按技术(软体解决方案、硬体、服务)
    • 依癌症类型(乳癌、肺癌、摄护腺癌、大肠癌、脑瘤、其他)
    • 按最终使用者(医院、外科中心和医疗机构等)
    • 按地区
    • 按公司分类(2024)
  • 市场地图

第六章:北美癌症诊断人工智慧市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美:国家分析
    • 美国
    • 加拿大
    • 墨西哥

第七章:欧洲癌症诊断人工智慧市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲:国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第八章:亚太地区癌症诊断人工智慧市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区:国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章:南美洲癌症诊断人工智慧市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲:国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第十章:中东和非洲癌症诊断人工智慧市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA:国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章:市场动态

  • 司机
  • 挑战

第 12 章:市场趋势与发展

第 13 章:全球癌症诊断人工智慧市场:SWOT 分析

第 14 章:竞争格局

  • Medial EarlySign
  • Cancer Center.ai
  • Microsoft Corporation
  • Flatiron Health
  • Path AI
  • Therapixel
  • Tempus Labs, Inc.
  • Paige AI, Inc.
  • Kheiron Medical Technologies Limited
  • SkinVision

第 15 章:策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 16238

The Global Artificial Intelligence in Cancer Diagnostics Market was valued at USD 128.47 million in 2024 and is projected to grow significantly, reaching USD 208.62 million by 2030 with a CAGR of 8.54% during the forecast period. AI is transforming cancer diagnostics by enabling faster, more accurate detection of malignancies through the analysis of complex medical data such as imaging scans and genomic profiles. As cancer incidence rises globally, the demand for early detection tools that enhance clinical outcomes is accelerating. AI-powered diagnostic platforms can identify subtle patterns in data that might elude traditional methods, improving accuracy while reducing diagnostic time and human error. This has proven particularly valuable for high-burden cancers like breast, lung, and colorectal cancer. Technological advancements, increasing cancer prevalence, and a strong push for precision medicine are key factors driving market expansion. Moreover, successful applications such as DELFI's AI blood test for liver cancer highlight the potential of AI to improve early-stage diagnosis and long-term survival.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 128.47 Million
Market Size 2030USD 208.40 Million
CAGR 2025-20308.54%
Fastest Growing SegmentHospital
Largest MarketNorth America

Key Market Drivers

Rising Cancer Incidence and Demand for Early Detection is Driving the Global Artificial Intelligence In Cancer Diagnostics Market

With cancer remaining a leading cause of death globally, early detection has become a top priority in healthcare systems. The growing incidence of cancer-attributed to aging populations, lifestyle factors, and environmental exposure-is driving demand for diagnostic tools that can catch tumors at their earliest and most treatable stages. AI is emerging as a game-changing technology in this regard. By analyzing extensive patient data, including radiologic and pathologic images, AI systems help clinicians identify malignancies faster and more accurately. For example, the American Cancer Society estimates over 2 million new cancer cases in the U.S. alone for 2024, underscoring the urgency for efficient diagnostic solutions. AI's ability to support rapid analysis and generate diagnostic insights across multiple cancer types enhances its value proposition, especially as healthcare providers seek scalable tools to meet increasing patient volumes and complexity in diagnostics.

Key Market Challenges

Data Quality and Quantity Poses a Significant Obstacle To Market Expansion

AI models require large, high-quality datasets to perform accurately and generalize effectively across populations. However, in cancer diagnostics, data availability and standardization remain significant hurdles. Variations in imaging protocols, inconsistent data labeling, and fragmented electronic health records can affect model training and limit diagnostic precision. Additionally, privacy concerns and regulatory barriers often restrict data sharing between institutions, limiting access to comprehensive datasets. These challenges slow the development of robust AI solutions and delay their clinical validation and deployment. Addressing this issue requires cross-institutional collaboration, anonymized data sharing frameworks, and rigorous data governance policies.

Key Market Trends

Technological Advancements

AI continues to advance rapidly, especially in areas such as machine learning, computer vision, and natural language processing. In cancer diagnostics, these technologies are enhancing image analysis, pathology workflows, and genomic profiling. AI algorithms now assist in detecting abnormalities in imaging scans with high precision, identifying early-stage tumors, and predicting treatment responses based on patient-specific genetic information. For instance, AI tools can detect textural or morphological changes in tissues that indicate early malignancies, which may not be visible to the human eye. Additionally, AI supports precision oncology by analyzing genomic mutations to match patients with targeted therapies. These technological innovations are improving diagnostic accuracy, reducing diagnostic delays, and enabling personalized treatment planning. As integration with clinical systems becomes more seamless, AI adoption in oncology diagnostics is expected to scale rapidly across healthcare institutions globally.

Key Market Players

  • Medial EarlySign
  • Cancer Center.ai
  • Microsoft Corporation
  • Flatiron Health
  • Path AI
  • Therapixel
  • Tempus Labs, Inc.
  • Paige AI, Inc.
  • Kheiron Medical Technologies Limited
  • SkinVision

Report Scope:

In this report, the Global Artificial Intelligence In Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Artificial Intelligence In Cancer Diagnostics Market, By Technology:

  • Software Solutions
  • Hardware
  • Services

Artificial Intelligence In Cancer Diagnostics Market, By Cancer Type:

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Brain Tumor
  • Others

Artificial Intelligence In Cancer Diagnostics Market, By End User:

  • Hospital
  • Surgical Centres and Medical Institutes
  • Others

Artificial Intelligence In Cancer Diagnostics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Artificial Intelligence In Cancer Diagnostics Market.

Available Customizations:

Global Artificial Intelligence In Cancer Diagnostics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

4. Global Artificial Intelligence In Cancer Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Software Solutions, Hardware, Services)
    • 5.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
    • 5.2.3. By End-User (Hospital, Surgical Centers and Medical Institutes, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Artificial Intelligence In Cancer Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Cancer Type
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Cancer Type
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Cancer Type
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Cancer Type
        • 6.3.3.2.3. By End-User

7. Europe Artificial Intelligence In Cancer Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Cancer Type
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Cancer Type
        • 7.3.1.2.3. By End-User
    • 7.3.2. United Kingdom Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Cancer Type
        • 7.3.2.2.3. By End-User
    • 7.3.3. Italy Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Cancer Type
        • 7.3.3.2.3. By End-User
    • 7.3.4. France Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Cancer Type
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Cancer Type
        • 7.3.5.2.3. By End-User

8. Asia-Pacific Artificial Intelligence In Cancer Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Cancer Type
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Cancer Type
        • 8.3.1.2.3. By End-User
    • 8.3.2. India Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Cancer Type
        • 8.3.2.2.3. By End-User
    • 8.3.3. Japan Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Cancer Type
        • 8.3.3.2.3. By End-User
    • 8.3.4. South Korea Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Cancer Type
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Cancer Type
        • 8.3.5.2.3. By End-User

9. South America Artificial Intelligence In Cancer Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Cancer Type
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Cancer Type
        • 9.3.1.2.3. By End-User
    • 9.3.2. Argentina Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Cancer Type
        • 9.3.2.2.3. By End-User
    • 9.3.3. Colombia Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Cancer Type
        • 9.3.3.2.3. By End-User

10. Middle East and Africa Artificial Intelligence In Cancer Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Cancer Type
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Cancer Type
        • 10.3.1.2.3. By End-User
    • 10.3.2. Saudi Arabia Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Cancer Type
        • 10.3.2.2.3. By End-User
    • 10.3.3. UAE Artificial Intelligence In Cancer Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Cancer Type
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Driver
  • 11.2. Challenges

12. Market Trends & Developments

13. Global Artificial Intelligence In Cancer Diagnostics Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Medial EarlySign
    • 14.1.1. Business Overview
    • 14.1.2. Cancer Type Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Key Personnel
    • 14.1.5. SWOT Analysis
  • 14.2. Cancer Center.ai
  • 14.3. Microsoft Corporation
  • 14.4. Flatiron Health
  • 14.5. Path AI
  • 14.6. Therapixel
  • 14.7. Tempus Labs, Inc.
  • 14.8. Paige AI, Inc.
  • 14.9. Kheiron Medical Technologies Limited
  • 14.10. SkinVision

15. Strategic Recommendations

16. About Us & Disclaimer